Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Lead Product(s): Erythropoietin EPO
Therapeutic Area: Hematology Product Name: rHuEPO
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: JSR Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 25, 2022